Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes. | ||||||||
|
Modified intrapleural cisplatin treatment for lung cancer with positive pleural lavage cytology or malignant effusion.Muraoka M, Oka T, Akamine S, Tagawa T, Morinaga M, Inoue M, Yamayoshi T, Hashizume S, Matsumoto K, Hayashi T, Nagayasu T Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki Graduate School of Biomedical Sciences, Nagasaki, Japan. ceb17760@hkg.odn.ne.jp OBJECTIVES: We evaluate the efficacy and safety of the modified intrapleural cisplatin treatment for lung cancer patients with positive pleural lavage cytology or malignant effusion. METHODS: The treatment was performed for seven patients with malignant effusion and 18 patents with positive pleural lavage cytology. After pulmonary resection, the pleural cavity was filled with cisplatin with a normal saline solution for 30 min. Complications and survival of the patients were evaluated. RESULTS: The chest tube duration were significantly prolonged in the treatment (CDDP) group (5.7 +/- 3.6 vs. 2.8 +/- 2.6 days). We had one operative death that developed a bronchial fistula; however, the other complications were not severe. The mortality rate was 4% and the morbidity rate was 60%. We experienced two carcinomatous pleuritis in the CDDP group. The median survival time of the CDDP group was 47.0 +/- 11.1 months and the 3- and 5-year survival rate was 52.6% and 11.3%, respectively. CONCLUSIONS: We were able to perform this treatment for these advanced lung cancer patients, which had the preventive effect of carcinomatous pleuritis. This therapy shows the possibility of a treatment that might lead to an improvement in the prognosis of these patients, without causing severe complications. Published 28 February 2006 in J Surg Oncol, 93(4): 323-9.
© 2004-2008 Lung Cancer Research Today. All Rights Reserved. |
| ||||||
